N-(o-tolyl)isobutyramide | 55577-63-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(o-tolyl)isobutyramide
• 英文别名: Isobuttersaeure-o-toluidid；o-Isobutyrotoluidide；2-methyl-N-(2-methylphenyl)propanamide
• CAS: 55577-63-4
• 化学式: C₁₁H₁₅NO
• mdl: MFCD01214237
• 分子量: 177.246
• InChiKey: OFPJBYSYCOQOHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(o-tolyl)isobutyramide 在 lithium aluminium tetrahydride 、 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-isopropyltryptamine
  参考文献：
  名称：

  Deconstruction of the α4β2 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator Desformylflustrabromine

  摘要：

  Desformylflustrabromine (dFBr; 1), perhaps the first selective positive allosteric modulator of alpha 4 beta 2 neuronal nicotinic acetylcholine (nACh) receptors, was deconstructed to determine which structural features contribute to its actions on receptors expressed in Xenopus ooycytes using two-electrode voltage clamp techniques. Although the intact structure of 1 was found to be optimal, several deconstructed analogs retained activity. Neither the 6-bromo substituent nor the entire 2-position chain is required for activity. In particular, reduction of the olefinic side chain of 1, as seen with 6, not only resulted in retention of activity/potency but in enhanced selectivity for alpha 4 beta 2 versus alpha 7 nACh receptors. Pharmacophoric features for the allosteric modulation of alpha 4 beta 2 nACh receptors by 1 were identified.

  DOI：

  10.1021/jm200834x
• 作为产物：
  描述：

  邻甲苯胺 在 氯仿 、 potassium carbonate 作用下， 生成 N-(o-tolyl)isobutyramide
  参考文献：
  名称：

  Tigerstedt, Chemische Berichte, 1892, vol. 25, p. 2920

  摘要：

  DOI：

文献信息

• Dioxanes and uses thereof
  申请人：——

  公开号：US20040072849A1

  公开（公告）日：2004-04-15

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): 1 and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 , R 3 , n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

  鉴于需要开发新型治疗剂和有效的合成方法，本发明提供了一般式(I)的新化合物： 1 及其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 ，n，X和Y如本文所定义。本发明还提供了包含一种式(I)化合物和药学上可接受的载体的药物组合物。本发明还提供了能够抑制组蛋白去乙酰化酶活性的化合物以及治疗由组蛋白去乙酰化酶活性调节的疾病的方法（例如，癌症和原虫感染），包括向需要的受体施用一种式(I)化合物的治疗有效量。本发明还提供了调节Ure2p下游葡萄糖敏感基因子集的方法。本发明还提供了制备本发明化合物的方法。
• PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BENAZET ALEXANDRE

  公开号：US20130079337A1

  公开（公告）日：2013-03-28

  The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1 , and also to the process for preparing them and to their therapeutic use.

  这项发明涉及与式（I）相对应的化合物，其中R1、R2和R3如权利要求1中所定义的，并且还涉及制备它们的过程以及它们的治疗用途。
• [EN] CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS<br/>[FR] DÉRIVÉS CARBAMOYLES DE CARBONYLAMINO-PYRAZOLES BICYCLIQUES COMME PROMÉDICAMENTS
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2009138440A1

  公开（公告）日：2009-11-19

  There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention.

  提供了公式(I)中的双环羰胺基吡唑化合物，其中变量如索赔中所述，用作药物，特别用于治疗由蛋白激酶（PKs）功能失调引起的疾病，如癌症，包括这种羰胺基衍生物的药物组合物，以及它们作为治疗活性剂的前药的用途。治疗方法和一些新的双环羰胺基吡唑也是本发明的对象。
• 一种N-芳基酰胺类化合物的制备方法
  申请人：广东石油化工学院

  公开号：CN111302967A

  公开（公告）日：2020-06-19

  本发明公开了一种N‑芳基酰胺类化合物的制备方法，包括如下步骤：（1）在配有磁力搅拌棒的Schlenk管中，装入二芳基碘鎓盐和Cu（OAc）2；（2）用注射器依次添加DCE、H2O和腈，将Schlenk管密封80℃搅拌反应；（3）将所得溶液冷却至室温，并用EtOAc萃取；合并有机层用盐水洗涤，并用无水Na2SO4干燥；（4）真空除去挥发物，残余物通过柱色谱法纯化得到N‑芳基酰胺类化合物。本发明经过大量实验，筛选了结构简单的底物，并且其反应条件温和、产率高、污染小，应用前景广阔。
• Ligand-free copper-catalyzed direct amidation of diaryliodonium salts using nitriles as amidation reagents
  作者：Hui-cheng Cheng、Lichao Zhou、Xuming Zhou、Jiao-li Ma、Penghu Guo、Yang Zhang、Hong-bing Ji

  DOI：10.1016/j.tetlet.2021.153048

  日期：2021.5

  efficient and practical methodology for the synthesis of N-arylamides has been developed via copper-catalyzed amidation of diaryliodonium salts with nitriles. Various substituted aryl nitriles and aliphatic nitriles could be applied in the reaction, providing a series of N-arylated amides in moderate to good yields. This procedure provides an alternative route for the synthesis of various N-arylamides

  通过铜催化的二芳基碘鎓盐与腈的酰胺化反应，已经开发出一种有效且实用 的合成N-芳基酰胺的方法。可以在反应中应用各种取代的芳基腈和脂族腈，以中等至良好的产率提供一系列的N-芳基化酰胺。该程序为合成各种N-芳基酰胺提供了另一种途径。还提出了一种基于控制实验的机制。